Trial Profile
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nebicapone (Primary) ; Levodopa/benserazide
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Bial
- 24 May 2016 New trial record